All In Biotech

Drug Trial Radar · NCT05832151

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

382

Actual

Start

Mar 27, 2023

Primary completion

Nov 14, 2025

Study completion Dec 12, 2025

Sponsor

Lead sponsor
CinDome Pharma, Inc.Industry
Sponsor type
Industry
First posted
Apr 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: * Screening period (1-2 visits) * Lead-in period (1 visit) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * Drug- CIN-102 Dose 15 mg or 10 mg * Drug- Placebo

Conditions

  • Diabetic Gastroparesis

Interventions

  • CIN-102 Dose 15mg or 10mgDrug

    2 capsules twice daily for 12 weeks

  • PlaceboDrug

    2 capsules twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting ScoresTime frame: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

Locations

100 sites in 1 country. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • G & L Research, LLC

    Foley, Alabama

  • Clinical Research Associates, LLC

    Huntsville, Alabama

  • Phoenix Medical Research Institute, LLC

    Peoria, Arizona

  • Onyx Clinical Research

    Phoenix, Arizona

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • Applied Research Center of Arkansas

    Little Rock, Arkansas

  • Arkansas Gastroenterology - North Little Rock

    North Little Rock, Arkansas

  • Alliance Research Institute - Bell Gardens

    Bell Gardens, California

  • Hope Clinical Research LLC

    Canoga Park, California

  • Alliance Research Institute, LLC

    Canoga Park, California

  • Erick H. Alayo Medical Corporation

    Chula Vista, California

  • GW Research Inc.

    Chula Vista, California

  • Kindred Medical Institute for Clinical Trials, LLC

    Corona, California

  • New Hope Research Development

    Corona, California

  • Aurora Care Clinic

    Costa Mesa, California

  • Paragon Rx Clinical

    Garden Grove, California

  • Valley View Wellness and Medical Center - VVCRD

    Garden Grove, California

  • Torrance Clinical Research Institute Inc.

    Lomita, California

  • Angel City Research

    Los Angeles, California

  • Facey Medical Research

    Mission Hills, California

  • Millennium Clinical Trials

    Thousand Oaks, California

  • Innovative Research of West Florida

    Clearwater, Florida

  • USA and International Research Inc.

    Doral, Florida

  • Advanced Medical Research Group

    Hollywood, Florida

  • Nature Coast Clinical Research

    Inverness, Florida

  • ClinCloud LLC

    Maitland, Florida

  • A+ Research Inc

    Miami, Florida

  • International Research Associates LLC - Breton

    Miami, Florida

  • Advanced Research Institute Inc

    New Port Richey, Florida

  • Gastroenterology of Greater Orlando

    Orange City, Florida

  • Tandem Clinical Research - Viera

    Viera, Florida

  • Summit Clinical Research, LLC

    Athens, Georgia

  • Atlanta Center for Gastroenterology P.C.

    Decatur, Georgia

  • Medisphere Medical Research Center

    Evansville, Indiana

  • Lutheran Medical Group

    Fort Wayne, Indiana

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas

  • DelRicht Clinical Research - Overland Park

    Overland Park, Kansas

  • Kansas Medical Clinic, P.A.

    Topeka, Kansas

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.